U.S. markets open in 4 hours 34 minutes

Xperi Holding Corporation (XPER)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
21.87+0.40 (+1.84%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close21.48
Bid17.10 x 800
Ask0.00 x 900
Day's Range21.60 - 22.03
52 Week Range9.01 - 22.09
Avg. Volume780,212
Market Cap2.312B
Beta (5Y Monthly)0.74
PE Ratio (TTM)N/A
EPS (TTM)-0.71
Earnings DateFeb 16, 2021 - Feb 22, 2021
Forward Dividend & Yield0.20 (0.93%)
Ex-Dividend DateNov 27, 2020
1y Target Est27.20
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Business Wire

    TiVo and Cox Communications Extend IP Agreement

    TiVo®, the company that brings entertainment together and a wholly-owned subsidiary of Xperi Holding Corporation (Nasdaq: XPER) today announced that Cox Communications has entered into a multi-year extension of its intellectual property agreement for the company’s media-related patent portfolios.

  • Programmable genetics gets more cash as Tessera Therapeutics gets a $230 million infusion

    Programmable genetics gets more cash as Tessera Therapeutics gets a $230 million infusion

    Tessera Therapeutics, the Boston-based spin-up from Flagship Pioneering, is the latest company to enter the mix with $230 million in new financing to build up its platform for better biological programming. The round was led by Alaska Permanent Fund Corp., Altitude Life Science Ventures and the second SoftBank Vision Fund, with participation from the Qatari Investment Authority and other undisclosed investors. Last year, the company took the covers off its gene-writing service, which combined an array of different gene editing, manufacturing and synthesizing technologies to provide more tailored therapeutic instructions to genetic code.

  • When Will Xperi Holding Corporation (NASDAQ:XPER) Breakeven?
    Simply Wall St.

    When Will Xperi Holding Corporation (NASDAQ:XPER) Breakeven?

    We feel now is a pretty good time to analyse Xperi Holding Corporation's ( NASDAQ:XPER ) business as it appears the...